

July 14-16, 2026 | Boston, MA
www.obesity-weight-loss-summit.com

REGISTER BY
MARCH 20 TO
SAVE \$1,000

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



4th Annual Obesity & Weight Loss Drug Development Summit

Advancing Best-In Class Obesity Therapies, From Novel Mechanisms to Human Impact

Developing Durable, Best-in-Class Therapies for Advancing Personalized, Next-Generation Drugs to Redefine Metabolic Quality & Accelerate the Shift From Acute Weight Loss to Sustainable Disease Modification

Expert Speakers Include:



Chien Li
Associate Director
Novo Nordisk



Kenneth Attie
Vice President,
Clinical Research &
Obesity
Eli Lilly & Co.



Dan Oieru
Medical Director,
Lead Cardiovascular
Renal Metabolics,
Product Development
Roche



Raj Reddy
Chief Executive
Officer
Canary Global



Ann Belien
Founder & Chief
Executive Officer
Rejuvenate Biomed



Philip Larsen
Chief Executive
Officer
SixPeaks Bio

Proud to Partner With:



+1 617 455 4188 @ info@hansonwade.com

www.obesity-weight-loss-summit.com



Welcome to the 4th Obesity & Weight Loss Drug Development Summit

Advancing the Precision Frontier & Sustainable Success

4th Annual
Obesity & Weight Loss
Drug Development Summit
July 14-16, 2026 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

The clinical success of GLP-1 receptor agonists marked a revolutionary first wave in metabolic medicine, fundamentally altering the treatment landscape for obesity. As we move through 2026, the market has entered a sophisticated new phase in which the focus has shifted from simple weight reduction to **quality of weight loss, long-term maintenance, and patient-centric delivery**. With the recent FDA approval of high-dose oral options and the debut of monthly maintenance injectables, the race for next-generation differentiation is no longer just about the scale, it's about metabolic health, muscle preservation, and global accessibility.

The **4th Obesity & Weight Loss Drug Development Summit** serves as the definitive industry meeting point. We are uniting **25+ expert speakers** from pharma giants and innovative biotechs, including **Novo Nordisk**, **Eli Lilly** and **Roche** to strategically dissect the crucial challenges of muscle atrophy, treatment rebound, and the transition from injectables to next-gen orals.

Join us at this unique, industry-led summit to:

- Assess the clinical outcomes and adherence benefits of oral small molecules versus ultra-long-acting injectables to gain a competitive edge by learning how to balance peak potency with the convenience required to dominate the burgeoning **maintenance market** with **CORXCEL Pharmaceuticals** and **Cirius Therapeutics**

- Address the archaic reliance on BMI by exploring new **FDA-aligned clinical endpoints** to learn to prioritize functional health and organ-specific metabolic recovery to secure regulatory approval and payer support in an increasingly crowded therapeutic landscape with **Veru Inc.**
- Tackle the critical challenge of "Sarcopenic Obesity" by delving into the science of decoupling adipose tissue reduction from skeletal muscle atrophy, ensuring patients lose fat, not strength, with specialized insights from **SixPeaks Bio** and **Merck & Co.**
- Master the evolution of Triple-Agonists (GLP-1/GIP/ Glucagon) and combination therapies and discover how to integrate these synergies to redefine the maximum weight loss potential while mitigating the side effects that often lead to treatment discontinuation with **Novo Nordisk**
- Utilize **genetics and proteomics** to predict patient-specific responses, reducing the 15% "non-responder" rate currently seen in clinics to strategize on durable maintenance protocols that prevent post-treatment weight regain to ensure lifelong health outcomes with **Canary Cure** and **Eli Lilly**

Join the **4th Obesity & Weight Loss Drug Development Summit** and be part of the conversation that will define the second wave of metabolic innovation. Ensure your pipeline delivers not just rapid weight loss, but the sustainable, high-quality health outcomes that will define the next decade of medicine.

Key Benefits of Attending



Join a high-impact workshop to navigate the evolving regulatory frontier and discover how to advance compounds by prioritizing **functional endpoints and metabolic health** over traditional weight-loss metrics, ensuring your pipeline aligns with the latest shifts in global clinical standards with **Veru Inc.**



Delve into the science of revolutionizing **combination and multi-agonist designs**, including the integration of **triple-agonists and GIP/GLP-1 synergies** and learn directly from industry leaders like **Novo Nordisk** on how to push the ceiling of maximum weight loss potential while maintaining therapeutic safety



Attend dedicated sessions on decoupling **adipose tissue reduction from skeletal muscle atrophy** and collaborate with **Merck & Co.** and **SixPeaks Bio** to prioritize muscle quality and function, transforming rapid weight loss into durable, long-term health outcomes that satisfy both patients and payers



Explore the future of the market by investigating **biological pathways beyond the incretin boom** and gain first-hand insights from **Scitherm Bio**, **Syntis Bio**, and **Energesis Pharmaceuticals** on novel, non-GLP-1 modalities designed to offer more tolerable, post-treatment maintenance regimens and secure consistent payer support



Participate in intensive sessions comparing **injectable peptides against oral small molecules** to determine the future of patient adherence and gain a competitive edge by learning how to balance **peak potency with long-term convenience** to dominate the burgeoning maintenance market with insights from **CORXCEL Pharmaceuticals** and **Cirius Therapeutics**

Defining the Second Wave to Beyond the Scale Into Sustainable Metabolic Health

4th Annual
Obesity & Weight Loss
Drug Development Summit
July 14-16, 2026 | Boston, MA

As we move through 2026, the market has entered a sophisticated new phase in which the focus has shifted from simple weight reduction to quality of weight loss, long-term maintenance, and patient-centric delivery. With the recent FDA approval of high-dose oral options and the debut of monthly maintenance injectables, the race for next-generation differentiation is no longer just about the scale; it is about metabolic health, muscle preservation, and global accessibility.

What's New for 2026?

This year's summit has been radically overhauled to align with the latest industry breakthroughs, representing a significant evolution from the 3rd annual meeting:

92% New Speaker Faculty: We have completely refreshed our expert lineup to bring you the most current perspectives from the front lines of metabolic R&D, featuring 25+ leaders from pharma giants like **Novo Nordisk**, **Eli Lilly**, and **Roche**

1

The "Sarcopenic Obesity" Mandate: While last year's event introduced muscle preservation, the 4th Summit dives deeper into the science of decoupling adipose tissue reduction from skeletal muscle atrophy, ensuring patients lose fat rather than strength

2

A Radical Regulatory Shift: Moving beyond last year's general regulatory overviews, this year features a high-impact workshop on advancing compounds by prioritizing functional endpoints and organ-specific metabolic health over traditional BMI metrics to align with the latest **Lancet Commission** frameworks.

3

The Maintenance Transition: With a new focus on the "post-incretin" era, we have introduced dedicated sessions on managing treatment rebound and the transition from injectables to next-gen oral maintenance continuums.

4

Marrying Industry Trends with Summit Strategy

The "Muscle Preservation" Crisis:

2026 clinical data confirms that rapid weight loss often comes at the cost of vital lean mass so Collaborate with **Merck & Co.** and **SixPeaks Bio** on muscle-targeted therapeutics that transform rapid weight loss into durable, long-term health outcomes

The "Incretin Rebound" Effect:

Increasing concern over weight regain once patients stop standard GLP-1 therapies so join us to Explore novel, non-GLP-1 modalities from **Scitherm Bio** and **Energesis Pharmaceuticals** designed to offer more tolerable post-treatment maintenance regimens

The Oral Delivery Race:

A global push to replace needle-based therapies with scalable, patient-friendly orals so strategize with **CORXEL Pharmaceuticals** on oral maintenance continuums that match bariatric outcomes while preserving functional vitality

New Companies in The Room



Your Expert Speakers

4th Annual
Obesity & Weight Loss
Drug Development Summit
July 14-16, 2026 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Large Pharma:



Kenneth Attie
Vice President, Clinical
Research & Obesity
Eli Lilly & Co.



Chien Li
Associate Director
Novo Nordisk



Hong Chen
Director, Search &
Evaluation
Novo Nordisk



Haleema Qamar
Research Scientist
Merck & Co



Dan Oieru
Medical Director, Lead
Cardiovascular Renal
Metabolics, Product
Development
Roche

Innovative Biotech:



Gary Barnette
Chief Scientific Officer
Veru Inc. & Ex FDA



Adi Gilboa-Geffen
Chief Technology Officer
Eleven Therapeutics




Harshini Neelakantan
Executive Director,
Research & Development
Ridgeline Therapeutics



Iris Grossman
Chief Therapeutics Officer
Eleven Therapeutics



Kalev Kask
Chief Executive Officer
Adge Pharmaceuticals



David Rosenbaum
Chief Development Officer
Syntis Bio




Mitchell Steiner
Chairman, Chief Executive
Officer & President
Veru Inc.



Olivier Boss
Chief Scientific Officer &
Founder
**Energesis
Pharmaceuticals**



Philip Larsen
Chief Executive Officer
Six Peaks Bio



Raj Reddy
Chief Executive Officer
Canary Global



Shreyas Singh
Associate Scientist I,
Formulation & Process
Development
Transpire Bio




Simon Bailey
President R&D
Unnatural Products Inc.



Mina Sooch
Strategic Advisor
Cirius Therapeutics




Cuauhtemoc Licon
Chief Scientific Officer
SciTherm Therapeutics




Ann Belien
Founder & Chief Executive
Officer
Rejuvenate Biomed



Roman Cailleateau
Chief Medical Officer
**CORXEL
Pharmaceuticals**



Linda Sasset
Senior Scientist
RenBio



Michael Lincoff
Chief Clinical Officer,
Canary Cure & Ex
Chair, Cardiovascular &
Renal Drugs Advisory
Committee, **FDA**

Pioneering Academics:



Janhavi Dalvi
Neonatologist
New York University

Pre-Conference Workshop Day

Tuesday, July 14, 2026

4th Annual
Obesity & Weight Loss
Drug Development Summit
July 14-16, 2026 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Morning Refreshments & Check-In

8.45

Workshop A

9.30

Understanding Genetics & Proteomics to Predict Patient Responses for More Personalized Treatments & Higher Success Rates Through Precision Medicine

This intensive workshop will delve into the cutting-edge integration of genetic and proteomic profiling to overcome the “one-size-fits-all” limitation of current obesity therapeutics. By leveraging high-resolution molecular data, participants will learn to transition from broad-spectrum weight loss approaches to precision-led development strategies that identify high-responders and mitigate non-response early in the pipeline. The session will focus on utilizing multi-omic insights to enhance trial predictability, minimize late-stage attrition, and deliver personalized cardiometabolic solutions with proven clinical superiority.

This session will cover:

- Implementing multi-omic patient stratification to move beyond BMI-based enrollment, using polygenic risk scores (PRS) and proteomic signatures to identify sub-populations with the highest probability of therapeutic response
- Decoding genetic drivers of non-response by analyzing the molecular heterogeneity of obesity (such as MC4R or INHBE variants) to predict why certain cohorts remain refractory to standard GLP-1/GIP therapies
- Utilizing proteomic biomarkers for early efficacy signals to identify real-time changes in metabolic health and adipose tissue distribution, providing objective proof-of-concept data long before significant weight loss is visible on the scale
- Integrating precision medicine into trial design through the use of biomarker-enriched protocols and adaptive “basket” trials that dynamically group patients based on their specific genetic metabolic drivers
- Establishing AI-driven predictive models that link large-scale genomic data to clinical outcomes, allowing development teams to optimize drug-target pairing and justify investment in personalized “next-generation” obesity assets
- Case study with Canary Cure: Integrating large-scale human genomic data and AI to identify the specific cross-talk between the CB1R and ZFP423 genes to deliver a dual gene-silencing therapy that precisely triggers the “browning” of white fat cells within 72 hours, ultimately providing an early proteomic proof-of-concept that identifies high-responders and secures a 25% increase in lean muscle mass for superior body composition results

Workshop Leaders



Raj Reddy
Chief Executive
Officer
Canary Cure

Lunch

12.30

“I valued the high quality of speakers and collegial atmosphere, the opportunity for all attendees to contribute and the multidisciplinary approach of pharma, biotech, CROs, RWE, and imaging organizations all in one”

Associate Vice President, **Eli Lilly**

Pre-Conference Workshop Day

Tuesday, July 14, 2026

4th Annual
**Obesity & Weight Loss
Drug Development Summit**
July 14-16, 2026 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Workshop B

1.30

Moving Beyond BMI & Weight-Loss Endpoints to Advance the Regulatory Frontier & Redefine Clinical Success with the FDA

This intensive workshop will delve into the critical shift from traditional BMI-centric metrics to a more sophisticated regulatory framework that reflects the true biological impact of next-generation obesity therapeutics.

As the FDA moves toward evaluating “quality of weight loss” and metabolic improvement, this session provides a strategic toolkit for biotechs to align their clinical endpoints with modern regulatory expectations. Central to this evolution is the Lancet Commission’s new framework, which offers a structured 18-point system to assess tissue and organ dysfunction. By differentiating between pre-clinical obesity (excess adiposity without dysfunction) and clinical obesity (impaired organ function), this framework allows for more precise patient stratification and offers a method to prioritize pharmacological or surgical interventions for those with the highest biological risk.

This session will cover:

- Integrating advanced body composition metrics to move beyond the limitations of the scale, utilizing DEXA and MRI data to quantify changes in visceral adipose tissue and lean muscle mass as primary or key secondary endpoints
- Defining meaningful metabolic endpoints by establishing validated links between drug-induced weight loss and the resolution of comorbidities such as MASH, CKD, and heart failure to support “beyond weight loss” label claims
- Designing trials for functional outcomes that measure improvements in physical mobility, exercise capacity, and respiratory function, providing the FDA with clear evidence of enhanced patient quality of life
- Navigating the regulatory path for maintenance and prevention by developing trial structures that satisfy FDA requirements for long-term safety and weight-regain prevention
- Establishing collaborative regulatory strategies for novel mechanisms (such as gene therapies or non-incretins) where traditional weight-loss benchmarks may not fully capture the drug’s therapeutic value

Workshop Leaders



Gary Barnette
Chief Scientific Officer
Veru Inc. &
Ex **FDA**



Michael Lincoff
Chief Clinical Officer, **Canary Cure** & Ex Chair,
Cardiovascular & Renal Drugs
Advisory Committee, **FDA**

End of Pre-Conference Workshop Day

4.30

“Pertinent topics, good speakers, terrific opportunity to network, several useful contacts resulted”

Director, Medical Merger & Acquisition, Scientific Advisory, **Novo Nordisk**

“I thoroughly enjoyed the summit for several reasons. First, the diversity of the speakers, both in terms of company size and roles within their organizations, was particularly enriching. The scientific talks were of high quality”

Director, Partnerships & Project Management, **CYTOO**

Conference Day One

Wednesday, July 15, 2026

4th Annual
Obesity & Weight Loss
Drug Development Summit
July 14-16, 2026 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



8.00 Morning Refreshments & Check-In



Dan Oieru
Lead Medical Director,
Cardiovascular Renal
Metabolics, Product
Development
Roche

8.50 Chair's Opening Remarks

Optimizing the Multi-Targeted Portfolio by Integrating Triple-Agonists & GIP/GLP-1 Synergies to Redefine Maximum Weight Loss Potential



Chien Li
Associate Director
Novo Nordisk

9.00 **Advancing Multi-Modal Incretin Synergies & Oral Maintenance Continuums to Match Bariatric Outcomes & Preserve Functional Vitality**

- Advancing the CagriSema portfolio (Semaglutide + Cagrilintide) to match bariatric outcomes, utilizing dual-pathway synergy between incretin and amylin receptors to drive deeper body weight reduction while specifically preserving physical vitality and metabolic rate
- Benchmarking REDEFINE clinical data against current "gold standard" dual-agonists to prove superior 68-week weight stability, providing the robust longitudinal data required for universal global payer support and expanded cardiovascular indication labeling
- Standardizing lean-mass-to-fat-mass ratios as a core regulatory endpoint in multi-targeted trials, ensuring that "maximum weight loss" translates into high-quality metabolic health and functional physical independence for aging populations



9.30 Session Reserved



10.00 **Speed Networking Session**

Put a face to a name – this session is the perfect opportunity to get face-to-face time with key opinion leaders, leading companies, and innovative researchers in obesity and weight loss drug development. Establish meaningful connections to build upon for the rest of the conference and gain individual insight beyond the papers and press releases into the pioneering research and therapeutic development.



10.30 Morning Break & Networking

Integrating Age-Specific Clinical Protocols to Address Unique Physiological Risks in Paediatric & Geriatric Patients, for Safer, More Effective Treatments



Janhavi Dalvi
Neonatologist
New York University

11.00 **Optimizing Lifecycle-Specific Pharmacotherapy by Integrating Age-Stratified Protocols to Mitigate Sarcopenic & Developmental Risks in Obesity Management**

- Implementing differentiated clinical monitoring frameworks that prioritize the preservation of lean muscle mass in geriatric cohorts and the protection of linear growth trajectories in pediatric patients to ensure long-term metabolic stability
- Utilizing granular, age-stratified dosing escalations that account for the divergent pharmacokinetic profiles of adolescent developmental plasticity versus geriatric renal and hepatic decline, minimizing gastrointestinal and systemic toxicity
- Leveraging remote physiological tracking and "High-Touch" multidisciplinary protocols to proactively manage the unique psychosocial and physical vulnerabilities of extreme age groups, ensuring treatment adherence without escalating patient fatigue

Conference Day One

Wednesday, July 15, 2026

8th Annual
**Obesity & Weight Loss
Drug Development Summit**
July 14-16, 2026 | Boston, MA



11.30 Session Reserved



Mitchell Steiner
CEO
Veru Inc.

12.00 Combating Sarcopenic Obesity in Geriatrics by Combining GLP-1s with Selective Androgen Receptor Modulators (SARMs) to Prevent Muscle Loss

- Adding oral selective androgen receptor modulators to standard incretin regimens to protect lean skeletal muscle mass during rapid weight loss, preventing the increased fall risk and frailty often seen in elderly patients on GLP-1s
- Utilizing advanced DEXA-based body composition analysis to prioritize “quality of weight loss” over simple BMI reduction, ensuring that weight loss translates into improved physical function and independence for the over-65 population
- Optimizing dual-therapy titration protocols to balance the appetite-suppressing effects of GLP-1s with the anabolic support of SARMs, delivering a comprehensive solution for geriatric obesity that satisfies both clinical and quality-of-life endpoints

12.30 Panel Discussion: Optimizing Next-Generation Delivery From Molecular Precision to Functional Resilience Improving Tissue Health Across the Lifespan

- Standardizing tissue-specific permeability and “molecular-reach” as a core regulatory endpoint to move beyond systemic bioavailability as the “gold standard” for pediatric and geriatric success, leading to a more nuanced and accurate reflection of metabolic health across all ages
- Evaluating the ethics and logistics of long-term “follow-on” studies to track the 10-year impact of incretins on muscle progenitor cell health and mitochondrial function, building the robust safety database required for universal pediatric approval
- Integrating objective metabolic-reserve metrics regarding “muscular-force” and “mitochondrial-efficiency” to capture the human impact of treatment, ensuring that drug development remains focused on functional longevity rather than just cosmetic weight loss



Harshini Neelakantan
Executive Director, Research & Development
Ridgeline Therapeutics



Simon Bailey
Chief Operating Officer & President, R&D
Unnatural Products Inc.



1.00 Lunch

Implementing Durable Maintenance Regimens to Prevent Post-Treatment Weight Regain, Securing Long-Term Health Outcomes & Consistent Payer Support

2.00 Body Composition Changes During Withdrawal from Weight Loss Medications: Insights from the BELIEVE Trial Extension and Metabolic Implications



Kenneth Attie
Vice President, Clinical Research, Obesity
Eli Lilly

- Comparing semaglutide and bimagrumab, alone or in combination, during 72 weeks treatment and 32 weeks withdrawal to understand actual changes in fat and lean mass by serial DXA measurements
- Quantifying differential effects on visceral fat, subcutaneous fat, and skeletal muscle of incretins and activin pathway inhibitors
- Implications for durable vs pharmacologic effects on adipose, muscle, and other tissues and the long-term cardio-metabolic consequences
- Incorporating follow-on studies to track the durability of benefits associated with various weight loss mechanisms and treatment strategies

Conference Day One

Wednesday, July 15, 2026

4th Annual
Obesity & Weight Loss
Drug Development Summit
July 14-16, 2026 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



Kalev Kask
Chief Executive Officer
Adge Pharmaceuticals

2.30 Correcting Metabolic & Inflammatory Imbalances for Healthy Lifespan

- Harnessing the SCAP/Insig1 pathway to downregulate SREBP-mediated lipogenesis, providing a direct physiological brake on fat accumulation that remains effective even after the intensive weight-loss phase of GLP-1 therapy is complete
- Utilizing miR-146a upregulation to mitigate hypothalamic senescence and systemic inflammation, restoring metabolic “resilience” and protecting against the weight-gain “rebound” triggered by standard hormonal therapies
- Implementing a low-dose, small molecule regimen that achieves a 55% reduction in visceral fat accumulation, offering an orally-deliverable maintenance solution that secures long-term cardiometabolic health and provides a clear value proposition for global payers



3.00 Session Reserved



Raj Reddy
Chief Executive Officer
Canary Cure

3.10 Beyond Appetite: Ultra-Long Duration CCT-217 Targets Energy Expenditure, Enhances Muscle Mass & Selectively Reduces Fat Mass to Treat Obesity with High Quality Weight Loss

- Introduction to the Modular Next Gen Hyper15™ Delivery Platform, the first technology capable of bypassing the endosome to successfully deliver dual siRNA payloads directly to adipose tissue. This breakthrough enables precise genetic silencing within the fat cell itself, treating the tissue as a metabolic organ rather than just a storage depot
- Differentiating CCT-217 from standard-of-care incretins by moving “Beyond Appetite.” We present data showing how silencing adipose-specific genes at their mitochondrial receptors unlocks thermogenic energy expenditure and lipolysis, driving weight loss through metabolic upregulation rather than caloric restriction/starvation physiology
- A deep dive into the compositional and commercial advantage of CCT-217. We demonstrate how CCT-217 delivers Selective Fat Mass reduction and Muscle Enhancement—avoiding the sarcopenic trap of GLP-1s—while offering an Ultra-Long Duration dosing profile (6+ months) that redefines treatment adherence



3.40 Afternoon Networking Break & Poster Session

Showcase your groundbreaking research and connect with peers in a vibrant, collaborative environment. Presenting at the poster session is your chance to gain visibility and engage directly with leading experts and innovators in the obesity drug development field. This is a unique opportunity to build new relationships and strengthen existing ones. Share your latest findings, gain valuable feedback, and explore potential collaborations that will shape the next generation of obesity and weight loss drugs.
To submit a poster, please contact info@hansonwade.com

Conference Day One

Wednesday, July 15, 2026

4th Annual
**Obesity & Weight Loss
Drug Development Summit**
July 14-16, 2026 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



Adi Gilboa-Geffen
Chief Technology
Officer
Eleven Therapeutics

4.30 **Harnessing AI-Driven xRNA Platforms to Deliver Ultra-Long-Acting Metabolic “Checkpoints” & Permanent Weight Stability**

- Utilizing the xRNA™ platform and “combinatorial genetics” to identify and silence high-impact metabolic targets, providing a “once-to-twice-a-year” dosing convenience that eliminates the daily or weekly “jab fatigue” associated with current peptide therapies
- Matching the durability of genetic interventions with a programmable siRNA design to offer a potent maintenance alternative, potentially capturing a dominant share of the post-incretin “transition market” by 2030 as payers demand therapies that prevent the \$100B+ biological “rebound effect”
- Optimizing the metabolic “hand-off” protocol by transitioning patients from acute GLP-1 induction to RNA-based physiological regulation, ensuring permanent appetite control and improved insulin sensitivity without the “peaks and troughs” or gastrointestinal side effects of chronic hormonal supplementation



Shreyas Singh
Associate Scientist I
Transpire Bio

5.00 **Maximizing Inhaled GLP-1 Bioavailability to Deliver Injectable-Strength Potency in a Scalable Portable Device for Improved Adherence**

- Engineering next-generation dry-powder (DPI) and soft-mist (SMI) inhalation platforms to leverage the lung’s massive vascular surface area, bypassing the gastric proteolytic barrier entirely
- Utilizing proprietary formulation technologies to deliver therapeutic peptide concentrations that achieve rapid systemic absorption, rivaling the pharmacokinetics of subcutaneous injectables without the need for needles
- Optimizing high-volume, state-of-the-art manufacturing processes (139,000 sq. ft. capacity) to bypass global constraints of “cold-chain” distribution and specialized injection hardware, ensuring global scalability



Dan Oieru
Lead Medical Director,
Cardiovascular Renal
Metabolics, Product
Development
Roche

5.30 **Chair’s Closing Remarks**

5.40 **End of Scientific Program Day 1**

“Highly relevant talks on the latest clinical use cases and development paths for obesity therapies. Senior decision makers from top tier pharma. CROs offering support services specific to development of therapies in this field”

CEO, **Nuanced Health**

“Really great topics and speakers. Energetic networking”

Director Business Development, **Summit Clinical Research**

Conference Day Two

Thursday, July 16, 2026

4th Annual
Obesity & Weight Loss
Drug Development Summit
July 14-16, 2026 | Boston, MA



7.30 Morning Refreshments



Dan Oieru
Lead Medical Director,
Cardiovascular Renal
Metabolics, Product
Development
Roche

8.20 Chair's Opening Remarks

Exploring Beyond the Incretin Boom to Investigate Next-Generation Biological Pathways & Pioneer Non-GLP-1 Modalities

8.30 **DNA-Encoded Metabolic Transformation by Leveraging In Vivo Protein Production to Redefine Durability & Dosing Paradigms Beyond Incretin Agonism**

- Harnessing the "Bio-Blueprint" via MYO Technology™ by utilizing proprietary DNA-encoded plasmid delivery to transform skeletal muscle or subcutaneous adipocytes into a sustainable bio-factory, enabling the continuous, endogenous production of therapeutic proteins that bypass the pharmacokinetic "spikes" and "troughs" of traditional biologics
- Engineering long-acting metabolic resilience by deploying the LNP-based Prometheus system to deliver genetic instructions for multi-pathway modulators (such as EX4 or modified GLP-1/GIP) that remain localized and active for over six months, providing a "one-and-done" metabolic reset that significantly improves liver and pancreatic function without systemic toxicity
- Pioneering a "Zero-Adherence" Treatment Framework by eliminating the psychological and physical hurdles of "jab fatigue" by replacing weekly or daily injections with ultra-long-acting DNA therapeutics, ensuring real-world efficacy that matches clinical trial performance by removing patient adherence from the therapeutic equation



Linda Sasset
Senior Scientist
RenBio

9.00 **Leveraging In-Silico Designed Thermogenics to Activate Selective Lipid Degradation Pathways for Sustained Fat Loss**

- Harnessing in-silico molecular design to engineer high-potency thermogenic candidates with superior target specificity, ensuring the activation of fat-burning pathways while avoiding the off-target cardiovascular effects common in historical thermogenic attempts
- Validating novel lipid-degradation variants through metagenomic adipocyte analysis and in-vitro lipolysis assays, providing a data-driven proof-of-concept for direct adipose tissue reduction independent of caloric intake
- Optimizing specificity for adipose tissue metabolism to inhibit lipid accumulation at the cellular level, delivering a durable metabolic solution that targets the root cause of obesity-related comorbidities



Cuauhtemoc Licona
Chief Scientific Officer
SciTherm Bio

9.30 **Replicating the Surgical "Gold Standard" by Utilizing a Synthetic Tissue-Lining to Mimic Gastric Bypass via a Once-Daily Pill**

- Utilizing a transient polydopamine polymer coating to precisely block nutrient absorption in the duodenum for 24 hours, providing a non-systemic "take-anytime" oral convenience that triggers the body's natural satiety cascade (GLP-1 and PYY) without the gastrointestinal side effects of exogenous peptide hormones
- Matching the 1% weekly weight-loss efficacy observed in preclinical models while achieving 100% preservation of lean muscle mass, offering a potent oral alternative that solves the "muscle-wasting" crisis of current injectables and could capture significant market share among patients seeking "healthy" functional weight loss
- Optimizing the metabolic environment of the small intestine to ensure steady-state glycemic control and appetite suppression, bypassing the "peaks and troughs" of injectable delivery and establishing a sustainable, low-cost maintenance therapy that prevents the biological "rebound" of weight regain



David Rosenbaum
Chief Development
Officer
Syntis Bio

Conference Day Two

Thursday, July 16, 2026

4th Annual
Obesity & Weight Loss
Drug Development Summit
July 14-16, 2026 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



Olivier Boss
Founder & Chief
Scientific Officer
Energesis
Pharmaceuticals

10.00 Increasing Thermogenic Adipocytes to Treat Obesity & Cardiometabolic Diseases

- All currently approved obesity drugs act by reducing food intake, causing a drop in metabolic rate (thermogenesis)
- To achieve durable weight control and cardiometabolic benefits, agents that increase metabolic rate are needed to complement existing therapies
- Energesis Pharmaceuticals is developing oral small molecules and proteins that boost energy expenditure - the missing therapeutic dimension in obesity treatment
- Energesis uses a proprietary platform of human brown/beige/brite adipocyte adult stem cells to discover novel targets and develop therapies that increase the amount of brown fat and induce long-term weight loss
- Our drug candidates drive robust fat-specific weight loss - without muscle loss - and show strong synergy with GLP-1 agents



10.30 Morning Break & Networking

Prioritizing Muscle Quality & Function to Decouple Adipose Tissue Reduction from Skeletal Muscle Atrophy Transforming Rapid Weight Loss into Sustainable Health



Philip Larsen
CEO
SixPeaks Bio

11.00 Engineering “Healthy Weight Loss” to Redefine Metabolic Quality via Precision Antibody-Peptide Conjugates (APCs) to Prevent Sarcopenia

- Utilizing an Activin IIA/B bispecific antibody to lift the “biological brake” on muscle growth, addressing the critical limitation of current GLP-1s where up to 40% of weight loss is derived from lean muscle mass
- Matching the fat-loss potency of high-dose injectables while simultaneously driving muscle hypertrophy, offering a “best-in-class” body composition profile that accelerates adipose-specific weight loss and boosts basal energy expenditure
- Optimizing the pharmacokinetic profile of lead candidate SPX-001 and its GLP-1 conjugates to ensure stable, monthly dosing that preserves metabolic fitness, prevents weight regain “rebound,” and provides a durable foundation for long-term cardiometabolic health



11.30 Session Reserved

11.40 Roundtable Discussion: Improving the Second Wave of Metabolic Innovation by Decoupling Mass Reduction from Functional Decline to Define Next-Generation Standards

Participate in an interactive, discussion-led session with industry experts to exchange diverse perspectives and solve complex industry challenges within the obesity drug development space without formal presentations.



Haleema Qamar
Research Scientist
Merck & Co.

- Standardizing “High-Quality Weight Loss” (HQL) indices as a core regulatory endpoint to move beyond “undifferentiated-mass-reduction” as the gold standard for adult and geriatric success, leading to a more nuanced and accurate reflection of metabolic health across the aging spectrum
- Evaluating the ethics and logistics of “metabolic-reset” benchmarks to track the off-treatment persistence of weight stability, building the robust safety database required for universal payer approval and long-term chronic management
- Integrating objective functional outcome assessments (FOAs) regarding “physical-resilience” and “metabolic-reserve” to capture the human impact of treatment, ensuring that drug development remains focused on functional longevity rather than just cosmetic weight loss

Conference Day Two

Thursday, July 16, 2026

4th Annual
**Obesity & Weight Loss
Drug Development Summit**
July 14-16, 2026 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

12.10 Exploiting Multi-Targeted Combinations to Preserve Muscle Quality & Functional Performance During GLP-1 Induced Weight Loss



Ann Belien
Founder & Chief
Executive Officer
Rejuvenate Biomed

- Harnessing the power of RJx-01 to target mitochondrial health, autophagy, and neuromuscular junction stability, providing a multimodal defense against the muscle strength loss often triggered by rapid weight loss
- Utilizing clinical proof-of-mechanism data that demonstrates significant improvements in muscle strength recovery and fatigue resistance in human subjects, ensuring muscle protection
- Implementing synergistic clinical development with GLP-1 agonists to decouple muscle strength loss from fat loss, ultimately delivering a superior “high-quality” weight loss profile that improves long-term patient mobility and clinical outcomes



12.40 Lunch

Navigating the Race Between Injectable Peptides & Next-Gen Oral Small Molecules to Balance Peak Potency & Long-Term Adherence to Dominate the Maintenance Market

1.40 Engineering Small-Molecule Potency to Deliver Injectable-Strength Efficacy in a Scalable Daily Pill for Long-Term Treatment



Roman Cailleteau
Chief Medical Officer
**CORXEL
Pharmaceuticals**

- Engineering next-generation small-molecule GLP-1 platforms to bypass the gastric proteolytic barrier, utilizing high-potency synthetic chemistry to deliver therapeutic concentrations that achieve weight-loss efficacy comparable to high-dose injectables (~9.7% reduction in 16 weeks) without the need for complex peptide absorption enhancers
- Implementing an “Oral-First” clinical strategy where patients bypass injectable induction entirely or transition to a long-term oral maintenance continuum, allowing companies to protect market share by offering highly tolerable, needle-free options for life-long weight stability and enhanced patient adherence
- Optimizing large-scale synthetic small-molecule manufacturing processes to bypass the global constraints of “cold-chain” distribution and specialized injection hardware, ensuring consistent drug availability to meet the projected 40%+ annual growth in global patient demand across U.S. and Asian markets

2.10 Reprogramming Mitochondrial Metabolism to Deliver Muscle-Preserving Efficacy in a Scalable Daily Pill to Offer Effective Alternative Treatment



Mina Sooch
Strategic Advisor
Cirius Therapeutics

- Engineering next-generation MPC-inhibitor platforms to bypass the gastric proteolytic barrier, utilizing selective mitochondrial reprogramming to deliver metabolic benefits that achieve muscle-preserving efficacy comparable to lean-body controls while augmenting the weight-loss power of high-dose injectables
- Implementing a “Synergy-First” clinical strategy where patients utilize oral MPC inhibitors alongside injectable induction or as a long-term maintenance continuum, allowing companies to protect market share by offering metabolic-correcting, needle-free options for life-long weight stability and the prevention of post-treatment regain
- Optimizing large-scale synthetic small-molecule manufacturing processes to bypass the global constraints of “cold-chain” distribution and specialized injection hardware, ensuring consistent drug availability to meet the projected 40%+ annual growth in global patient demand for high-quality, body-composition-focused obesity care

Conference Day Two

Thursday, July 16, 2026

4th Annual
**Obesity & Weight Loss
Drug Development Summit**
July 14-16, 2026 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

2.40 Roundtable Discussion: The Maintenance Inflection Point: Transitioning from Clinical-Procedure Injections to Daily Prescriptive Habits for Life-Long Stability



Iris Grossman
Chief Therapeutics
Officer
Eleven Therapeutics

- Synthesizing “injectable-strength” efficacy in oral formats to challenge the historical potency gap, evaluating how synthetic small-molecule platforms are bypassing gastric proteolytic barriers to achieve double-digit weight loss without the strict fasting requirements or the bioavailability limitations of traditional oral peptides
- Assessing the “persistence-pivot” from induction to maintenance, examining real-world adherence data to determine if the convenience of a needle-free daily pill can overcome the 90-day discontinuation risk prevalent in long-term injectable therapy, effectively securing a stable market share in the chronic management phase
- Strategizing for global scalability and payer alignment by leveraging the cost and distribution advantages of synthetic manufacturing to bypass the “cold-chain” bottleneck, ensuring that the next wave of metabolic innovation can meet the 85 million-patient demand while providing the robust evidence required for universal insurance coverage

3.10 Panel Discussion: The 2030 Vision - Shifting from Acute Weight Loss to Sustainable Disease Modification & Integrated Cardiometabolic Health

- Prioritizing the resolution of co-morbidities such as MASH, CKD, and heart failure to move beyond BMI reduction as the sole metric of clinical success, establishing obesity drugs as essential “foundation therapies” for lifelong cardiometabolic protection
- Implementing evidence-based “step-down” protocols, transitioning patients from high-dose injectable peptides to low-dose oral small molecules or RNA-based silencers to suppress the biological “rebound effect” after reaching goal weight for durable weight stability and higher long-term therapy persistence
- Integrating longitudinal data on physical function, hospitalization rates, and employment status to quantify the total economic value of long-term obesity treatment, providing a robust scientific justification for expanded reimbursement and universal patient access across diverse socioeconomic populations



Raj Reddy
Chief Executive Officer
Canary Cure



Olivier Boss
Founder & Chief Scientific Officer
Energesis Pharmaceuticals



Michael Lincoff
Chief Clinical Officer, **Canary Cure** & Ex Chair,
Cardiovascular & Renal Drugs Advisory Committee, **FDA**



Hong Chen
Director, Search & Evaluation
Novo Nordisk



Dan Oieru
Lead Medical Director,
Cardiovascular Renal
Metabolics, Product
Development
Roche

3.40 Chair's Closing Remarks

3.50 End of Scientific Program Day 2



Lead Partner

AMRA Medical is a health informatics and precision medicine company that is pioneering body composition analysis, providing cutting-edge solutions to advance both clinical research and patient care initiatives. AMRA's gold-standard technology delivers multiple fat and muscle biomarkers - derived simply from rapid whole-body MRI scans. AMRA is committed to driving transformative care and simplifying vital decision-making in both research and clinical settings by offering support services via their innovative platform to help advance disease research in obesity, and beyond.

www.amramedical.com



Program Partner

Antaros Medical is pioneering imaging methods, using MRI* and PET**, to both design and deliver clinical imaging studies. Applied with our extensive experience and expertise in drug development and disease biology, our tailored solutions have helped our customers to solve complex problems to empower confident decision-making at every stage of clinical drug development, from small mechanistic studies to large scale studies. Disease areas: CV, renal and metabolic diseases and oncology.

www.antarosmedical.com



Innovation Partner

Physiogenex is a preclinical CRO providing original and benchmarked animal models of obesity/type 2 diabetes and related co-morbidities: MASH, dyslipidemia, inflammation, diabetic nephropathy, HFpEF and atherosclerosis. For >20 years, we have been evaluating the efficacy of our clients' drugs using goldstandard experiments in our validated preclinical models. Our customers benefit from our experience in drug development and expertise in metabolic diseases, as demonstrated by our numerous co-publications with our industrial partners. Our expertise – your success.

www.physiogenex.com



Innovation Partner

CYTOO is a biotech company focused on muscle health. Its MyoScreen™ platform models key features of inherited and acquired muscle diseases, enabling in vitro screening of relevant phenotypes, biomarkers and pathways. Combined with expertise in assay development and AI-driven image analysis, MyoScreen supports drug development across the pipeline, including disease modeling, primary and secondary screening to candidate characterization and potency assays for batch release. MyoScreen has helped advance drugs into trials during over 60+ industry partner projects. To support sponsor's CMC activities, CYTOO is setting up a GMP facility, operational by end 2025.

www.cytoo.com



Exhibition Partner

Biomere is a growing preclinical contract research organization (CRO) based in the greater Boston area (Worcester MA). Biomere's facility includes multiple floors of vivarium space for rodents and large animals, and laboratory spaces. Our core areas of expertise are preclinical non-GLP PK/PD studies and early toxicology studies in rodent and large animal models. Our team of scientists have specialty expertise in models that include surgical services and specialized dosing routes. Biomere is AAALAC accredited, OLAW Assured, DEA Licensed, and USDA Registered.

www.biomere.com

Take the Spotlight – Partner with Us

4th Annual
Obesity & Weight Loss
Drug Development Summit
July 14-16, 2026 | Boston, MA

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Your Global Platform to Forge Strategic Alliances & Capitalize on the \$150bn Obesity “Gold Rush”

With M&A activity hitting record highs and the market projected to soar by 2035, the industry is in a high-stakes “land grab” for next-gen assets. As Big Pharma aggressively deploys capital to bridge the patent cliff, your innovation is the missing piece in their multi-billion dollar pipelines. Position your brand at the center of this investment frenzy to secure the strategic partnerships and premium valuations defining the 2026 market.



Demonstrate your technical superiority in front of **120+ senior decision-makers** from titans like **Novo Nordisk**, **Eli Lilly**, and **Merck** by showcasing your specialized **preclinical muscle models**, **advanced imaging biomarkers (MRI/CT)** for body composition, and **clinical CRO site-coordination** strategies, to position your brand as the “go-to” partner for sponsors needing to prove high-quality weight loss and muscle-sparing efficacy in a crowded GIP/GLP-1 market.




Inform your 2026 commercial strategy by gaining an “inner circle” view of the shifting regulatory landscape and use our dedicated workshops to understand how industry leaders are successfully pivoting toward **functional endpoints beyond BMI** to align your Biomarker and HEOR offerings with the new regulatory demand for evidence of organ-specific metabolic recovery and long-term safety.




Elevate your brand presence within a highly targeted community of key industry figures redefining the multi-billion dollar weight-loss sector. Whether you provide **Real-World Evidence (RWE)** to support payer negotiations, **HEOR data analysis** to prove cost-effectiveness, or **Clinical CRO services** to accelerate proof-of-concept, this summit provides the intimate networking environment needed to secure the multi-year collaborations that drive long-term commercial advantage.

Seniority of Attendees



Type of Companies Attending



*Based on previous iterations of the Obesity & Weight Loss Drug Development Summit

Get Involved



Molly Biggin
Partnerships Director
Tel: +1 617 455 4188
Email: sponsor@hansonwade.com

Ready to Register?

3 Easy Ways to Book

 <https://obesity-weight-loss-summit.com/register/>

 Tel: +1 617 455 4188

 Email: info@hansonwade.com



Analyze the core challenges and advance solutions in **multi-agonist development** (GIP, GCG, Amylin) and explore **next generation biological pathways** to ensure the second wave of metabolic medicines deliver superior “**quality of weight loss**” and a sustainable competitive edge



Uncover how industry leaders are balancing **peak potency with long-term adherence** through next-gen oral small molecules and durable maintenance regimens to succeed in an increasingly crowded market and secure long-term payer support



Gain critical insights into creating safer, more effective treatments by tailoring protocols for the unique physiological risks of **pediatric and geriatric patients**, ensuring high success rates through individualized precision medicine

Drug Developers	Register & Pay By Friday, March 20	On the Door Price
Conference + 2 Workshops	\$3,097	\$3,597
Conference + 1 Workshop	\$2,648	\$3,148
Conference Only	\$2,199	\$2,699

Academic & Research Institutes**	Register & Pay By Friday, March 20	On the Door Price
Conference + 2 Workshops	\$2,497	\$2,997
Conference + 1 Workshop	\$2,148	\$2,648
Conference Only	\$1,799	\$2,299

Solution & Service Providers	Register & Pay By Friday, March 20	On the Door Price
Conference + 2 Workshops	\$4,397	\$5,397
Conference + 1 Workshop	\$3,898	\$4,648
Conference Only	\$3,399	\$3,899

*To qualify for the drug developer rate your company must have a public drug pipeline. Please visit the website for full pricing options or email info@hansonwade.com
Do you work for a Not-for-Profit organization? Email us at info@hansonwade.com to inquire about attending

**To qualify for academic & research rate you must be full time academic. Please visit the website for full pricing options or email info@hansonwade.com


Team Discounts***

- 10% discount – 2 Attendees
- 15% discount – 3 Attendees
- 20% discount – 4+ Attendees

***Please note that discounts are only valid when two or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: register@hansonwade.com



Venue

Hotel Commonwealth
500 Commonwealth Avenue, Boston, MA 02215
<https://www.hotelcommonwealth.com/>

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Hanson Wade Ltd, Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom